SELLAS GPS Trial Nears Completion as Survival Times Extend Beyond Expectations
SELLAS Life Sciences' Phase 3 REGAL trial for GPS in AML patients approaches 80-event threshold with 72 deaths reported, suggesting potential survival benefits as stock surges 100% in December.